Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2016. The filing identifies the issuer as Celsion Corporation (not Imunon, Inc.); investors should confirm the requested company and filing match. Celsion was a clinical-stage oncology drug developer with no material product sales. Its lead candidate, ThermoDox, was in a Phase III liver-cancer trial and a Phase II recurrent chest-wall breast-cancer trial; GEN-1 was in early-stage ovarian-cancer development.
Financial results and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $375,000 | $375,000 |
| Research and development | $4.23 million | $2.88 million | $11.00 million | $10.96 million |
| Operating expenses | $5.72 million | $4.37 million | $15.89 million | $16.27 million |
| Net loss | $6.41 million | $4.27 million | $16.66 million | $16.95 million |
| Basic and diluted loss per share | $0.23 | $0.19 | $0.66 | $0.79 |
Gross margin is not a meaningful reported measure given the company’s minimal licensing revenue and development-stage operations. Q3 operating loss was $5.60 million, versus $4.24 million a year earlier; the nine-month operating loss improved to $15.52 million from $15.90 million.
- Cash flow: Nine-month operating cash use was $13.72 million; investing activities provided $6.24 million and financing activities provided $2.40 million. Cash and equivalents declined by $5.08 million to $4.18 million.
- Liquidity: Cash and short-term investments totaled $8.70 million at September 30, 2016, compared with approximately $20.1 million at December 31, 2015. Current assets were $9.03 million and current liabilities $9.76 million, a working-capital deficit of approximately $0.73 million.
- Debt and other obligations: Notes payable had a $3.59 million carrying value, with $3.32 million principal scheduled for repayment during the year ending September 30, 2017. The Hercules loan bore interest at 11.50%. The EGEN earn-out milestone liability was $14.48 million.
- Equity: Stockholders’ equity was $10.57 million; accumulated deficit was $235.67 million. The company raised approximately $6.0 million gross in a June 2016 offering and reported 26.06 million common shares outstanding at quarter-end.
Material changes versus the prior comparable period
- Q3 R&D rose 46.5%, driven chiefly by OPTIMA enrollment, treatment and site-startup costs, and other clinical work supporting ThermoDox studies in Europe. Nine-month R&D was nearly unchanged as lower manufacturing and GEN-1 costs offset higher clinical spending.
- Q3 net loss widened by about $2.14 million. In addition to higher operating costs, the period included a $662,410 non-cash charge from revaluing the EGEN earn-out liability; the comparable 2015 quarter had a $282,950 non-cash gain.
- Nine-month net loss was modestly lower than in 2015, while lower interest expense and general and administrative costs helped offset clinical spending. Cash and investments fell substantially, and working capital shifted from an $11.0 million surplus at year-end 2015 to a deficit.
- In August 2016, Celsion signed a GEN-1 manufacturing and supply agreement with Hisun for China, with possible expansion subject to regulatory approvals.
Outlook, commentary and key risks
- Management estimated that September-end cash and short-term investments, together with access to its at-the-market equity facility, would fund operations into the second quarter of 2017. The filing states there are no other committed financing sources and warns that failure to raise funds would create substantial doubt about the company’s ability to continue as a going concern. Further equity financing could dilute existing holders; insufficient funds could force delays, reductions or termination of programs.
- The filing gives no formal revenue or earnings guidance. Management expected substantial operating losses and cash needs to continue while it develops candidates and conducts trials.
- ThermoDox’s earlier Phase III HEAT trial failed its primary progression-free-survival endpoint. Management highlighted favorable retrospective overall-survival analyses in a selected subgroup and reported an independent NIH analysis with similar findings; these analyses do not establish success in the ongoing OPTIMA trial. Management expected OPTIMA enrollment to be completed in the first half of 2018.
- Early OVATION results involved only six patients; the independent safety board recommended proceeding to the fourth and final cohort. These preliminary observations are not confirmatory evidence of efficacy.
- Other key risks include clinical and regulatory failure or delay, reliance on external trial and manufacturing partners, uncertain access to capital, potential shareholder dilution, and Nasdaq listing compliance. The filing reported a $0.92 closing share price on November 9, below the $1.00 minimum bid threshold discussed in its risk factors.
- The company reported no legal proceedings and no material change in internal control over financial reporting; management considered disclosure controls effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Celsion Corporation, although the request names Imunon, Inc.
- Clarify equity-facility availability: the filing variously cites approximately $17.4 million remaining under the ATM agreement and $7.5 million available/registered under the relevant offering materials. Verify the amount actually accessible and the conditions on its use.
- Track cash burn, financing needs and runway against management’s second-quarter 2017 estimate, including any subsequent equity issuance and dilution.
- Assess the prospective OPTIMA trial separately from post-hoc HEAT subgroup analyses, and monitor enrollment, interim reviews and regulatory communications.
- Review the June 2016 warrant overhang: the filing reports 15.95 million warrants outstanding at September 30, including warrants associated with the financing, alongside additional options and equity awards.
- Monitor Nasdaq bid-price compliance, the Hercules repayment schedule, and changes in the fair value or potential payment of the EGEN earn-out.